Table 1.
Clinical Characteristics Between Training Set and Testing Set
| Characteristics | Training Set (n=89) | Testing Set (n=38) | P-value |
|---|---|---|---|
| Age, mean (SD), years | 51.57±10.88 | 51.47±9.40 | 0.959 |
| Tumor size | 4.01±1.80 | 3.95±1.70 | 0.856 |
| Rad-score | −0.02±0.65 | 0.06±0.65 | 0.499 |
| Menopausal status | 0.473 | ||
| Premenopausal | 27 (27.78%) | 14 (35.61%) | |
| Postmenopausal | 62 (72.22%) | 24 (64.39%) | |
| Enhancement pattern | 0.411 | ||
| Mass | 65 (73.03%) | 25 (65.79%) | |
| Non-mass | 24 (26.97%) | 13 (34.21%) | |
| Multifocal or multicenter | 0.940 | ||
| Present | 24 (26.97%) | 10 (26.32%) | |
| Absent | 65 (73.03%) | 28 (73.68%) | |
| Mass shape | 0.841 | ||
| Round/oval | 8 (8.99%) | 3 (7.89%) | |
| Irregular | 81 (91.01%) | 35 (92.11%) | |
| Tum margin | 0.598 | ||
| Circumscribed | 42 (47.19%) | 16 (72.73%) | |
| Not circumscribed | 47 (52.81%) | 22 (27.27%) | |
| Internal enhancement | 0.227 | ||
| Homogeneous | 11 (12.36%) | 2 (5.26%) | |
| Heterogeneous | 78 (87.64%) | 36 (94.74%) | |
| Pre-NAC T stage | 0.740 | ||
| T2 | 63 (70.79%) | 28 (73.68%) | |
| T3 | 26 (29.21%) | 10 (26.32%) | |
| Pre-NAC N stage | 0.400 | ||
| N0 | 30 (33.71%) | 9 (23.68%) | |
| N1 | 44 (49.44%) | 23 (60.52%) | |
| N2 | 5 (5.62%) | 2 (5.26%) | |
| N3 | 10 (11.23%) | 4 (10.54%) | |
| Ki67 | 0.220 | ||
| High | 72 (80.89%) | 27 (71.05%) | |
| Low | 17 (19.11%) | 11 (28.95%) | |
| Type of surgery | 0.234 | ||
| Conservation | 17 (19.10%) | 4 (10.53%) | |
| Radical surgery | 72 (80.90%) | 34 (89.47%) | |
| PCR | 0.22 | ||
| Yes | 32 (35.95%) | 22 (57.89%) | |
| No | 57 (64.05%) | 16 (42.11%) |
Abbreviations: NAC, neoadjuvant chemotherapy; PCR, pathological complete response; SD, standard deviation.